Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases

The authors report the use mycophenolate mofetil (MM) in the treatment of n euromuscular diseases. Thirty-eight patients (32 with MG, three with inflam matory myopathy, and three with chronic acquired demyelinating neuropathy) were treated with MM for an average duration of 12 months. All patients tol erated MM without major side effects. Twenty-four patients improved either in their functional status or in their ability to reduce corticosteroid dos e. Mean time to improvement was 5 months.